Cytokinetics, Incorporated
CYTK
$38.34
$0.290.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 4,128.56% | -90.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4,128.56% | -90.67% | |||
| Cost of Revenue | 12.73% | 6.63% | |||
| Gross Profit | 53.41% | -28.11% | |||
| SG&A Expenses | 14.56% | -7.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.40% | 0.80% | |||
| Operating Income | 28.35% | -11.93% | |||
| Income Before Tax | 16.73% | -7.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 16.73% | -7.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.73% | -7.57% | |||
| EBIT | 28.35% | -11.93% | |||
| EBITDA | 28.77% | -12.20% | |||
| EPS Basic | 17.41% | -7.19% | |||
| Normalized Basic EPS | 17.41% | -7.19% | |||
| EPS Diluted | 17.41% | -7.19% | |||
| Normalized Diluted EPS | 17.41% | -7.19% | |||
| Average Basic Shares Outstanding | 0.81% | 0.36% | |||
| Average Diluted Shares Outstanding | 0.81% | 0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||